Ipsen S.A. is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. The firm's primary focus is on specialty care, targeting thr... Ipsen S.A. is a global biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. The firm's primary focus is on specialty care, targeting three core therapeutic areas: oncology, neuroscience, and rare diseases. With an extensive portfolio, Ipsen offers well-known brands such as Somatuline for neuroendocrine tumors, Cabometyx for oncology, Dysport for movement disorders, and Bylvay for rare diseases. The company maintains an active research pipeline with several candidates in various stages of clinical development across its key areas, including both established treatments and emerging therapies for conditions with significant unmet medical needs. Founded in 1929 and headquartered in France, Ipsen plays a significant role in advancing medical science and improving patient outcomes worldwide. Its presence in major pharmaceutical markets, commitment to innovation, and focus on specialized medicine have made it a noteworthy player in the healthcare sector, with both a robust commercial footprint and a reputation for research excellence.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for Ipsen

We have not yet reviewed Ipsen's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Ipsen's data?

Start your 30-day free trial to request a data review for Ipsen.

Start Free Trial

Legal Center Contact Us